Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K123977
    Date Cleared
    2013-11-21

    (330 days)

    Product Code
    Regulation Number
    862.1215
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    K951223, K041361

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Randox Liquid CK-MB: The Randox Liquid CK-MB test system is a device intended for the quantitative in vitro determination of CK-MB concentration in serum and plasma. Measurements of CK-MB are used in the diagnosis and treatment of myocardial infarction (MI). This product is suitable for use on the RX series instruments including the RX Daytona and the RX Imola.
    Randox CK-MB Calibrator: The Randox CK-MB calibrator is an in vitro diagnostic product intended for use in the calibration of Randox CK-MB methods.
    The Randox Liquid CK-MB test system for the RX Imola is a prescription use device intended to be used in clinical laboratories only.

    Device Description

    Liquid CK-MB is supplied in a kit containing:

    • 4 x 20.0 mL CK-MB Buffer
    • 4 x 6.0 mL CK-MB Substrate.
      The CK-MB calibrator is lyophilised, single analyte, human serum based product. The kit contains ten vials (single level) with 1.0 mL per vial. Double de-ionised water is required for reconstitution.
    AI/ML Overview

    Here's a summary of the acceptance criteria and the study details for the Randox Liquid CK-MB and Randox CK-MB Calibrator, based on the provided text:

    1. Acceptance Criteria and Reported Device Performance

    The document outlines performance characteristics rather than explicit "acceptance criteria" in a pass/fail table. However, implied acceptance is demonstrated by the reported empirical results.

    Performance CharacteristicAcceptance Criteria (Implied by Study Design)Reported Device Performance (RX Daytona)Reported Device Performance (RX Imola)
    Precision (Total CV%)No explicit criteria given, but results are expected to be low and consistent.10.9% (at 9.90 U/L), 2.9% (at 1011.98 U/L), 2.5% (at 244.85 U/L), 2.8% (at 437.45 U/L), 3.3% (at 47.53 U/L), 2.5% (Calibrator), 3.2% (Control)12.5% (at 10.38 U/L), 4.0% (at 1001.29 U/L), 3.4% (at 245.62 U/L), 3.3% (at 437.83 U/L), 5.0% (at 47.43 U/L), 3.3% (Calibrator), 2.8% (Control)
    Linearity/Reportable RangeDeviation from linearity less than 5% within the claimed range.7 - 2000 U/L6 - 1100 U/L
    Extended Recovery± 10%10200 U/L ± 10%10200 U/L ± 10%
    Limit of Detection (LoD)Not explicitly stated, but lower values indicate better sensitivity.5.06 U/L2.41 U/L
    Limit of Blank (LoB)Not explicitly stated, but lower values indicate better sensitivity.2.91 U/L0.87 U/L
    Limit of Quantitation (LoQ)≤20% accuracy and ≤20% imprecision.7.00 U/L6.00 U/L
    Analytical Specificity (Interference)% of Control ± 10%Met for all tested interferents (except Intralipid*)Met for all tested interferents (except Intralipid*)
    Method Comparison (Correlation with Predicate)High correlation (strong linear relationship)r = 0.999 (Y = 0.95 + 0.59)r = 0.999 (Y = 0.96 + 2.36)
    Matrix Comparison (Correlation with Serum)High correlation (strong linear relationship)r = 1.000 (Lithium Heparin), r = 0.999 (Potassium EDTA)r = 0.999 (Lithium Heparin), r = 1.000 (Potassium EDTA)
    Expected Values/Reference RangeAll values reported in the expected range for Healthy Individuals (
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1